Caris Life Sciences (CAI) Revenue (2024 - 2026)

Caris Life Sciences' Revenue history runs 3 years deep, the most recent figure standing at $216.2 million for Q1 2026.

• In Q1 2026, Revenue rose 78.78% year-over-year to $216.2 million; the TTM figure through Mar 2026 stood at $907.3 million (up 100.51% YoY), while the FY2025 annual figure was $812.0 million, up 96.97% from the prior year.
• Revenue was $216.2 million for Q1 2026 at Caris Life Sciences, down from $292.9 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $292.9 million in Q4 2025 to a low of $100.0 million in Q2 2024.
• Historically, Revenue has averaged $170.0 million across 3 years, with a median of $155.7 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Revenue soared 125.44% in 2025, then jumped 78.78% in 2026.
• A 3-year view of Revenue shows it stood at $129.9 million in 2024, then surged by 125.44% to $292.9 million in 2025, then dropped by 26.19% to $216.2 million in 2026.
• The last three Revenue figures came in at $216.2 million (Q1 2026), $292.9 million (Q4 2025), and $216.8 million (Q3 2025), per Business Quant data.